Indivior Pharmaceuticals Inc (INDV) Stock: Price, Forecast & Analyst Target

Indivior Pharmaceuticals Inc Company Overview

Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs. Their focus is on treating opioid dependence, co-occurring disorders, and other substance use disorders.

Indivior Pharmaceuticals Inc. focuses on developing and selling buprenorphine-based prescription drugs for opioid dependence. The company operates globally, with a significant presence in the United States, United Kingdom, and other international markets.

Key Facts

• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic
• Headquarters: North Chesterfield, VA, US
• CEO: Joseph J. Ciaffoni
• Employees: 1030

What Indivior Pharmaceuticals Inc Does

Develops buprenorphine-based prescription drugs for opioid dependence.,Manufactures medications like Suboxone Film, Suboxone Tablet, and Subutex Tablet.,Sells its products in the United States, United Kingdom, and other international markets.,Focuses on treating opioid dependence and related substance use disorders.,Conducts research and development to create new addiction treatments.,Works with healthcare providers to improve access to addiction treatment.,Engages in advocacy and awareness initiatives related to opioid dependence.

Business Model

Develops and patents proprietary formulations of buprenorphine-based medications.,Manufactures and distributes its products through established pharmaceutical supply chains.,Generates revenue through the sale of prescription drugs to healthcare providers and pharmacies.,Invests in research and development to expand its product pipeline and improve existing treatments.

Key Competitors

Praxis Precision Medicines, Inc., Lantheus Holdings, Inc., Crinetics Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Hinge Health, Inc.

INDV Investment Analysis

Investment Thesis

Indivior Pharmaceuticals Inc. presents a compelling investment case centered on its specialization in addiction treatment, particularly opioid dependence. With a P/E ratio of 19.47 and a strong gross margin of 83.1%, the company demonstrates financial stability and profitability. Key value drivers include the ongoing demand for opioid dependence treatments and Indivior's established market presence with products like Suboxone Film. Growth catalysts involve expanding its product pipeline to address co-occurring disorders and other substance use disorders. Potential risks include regulatory challenges, competition from generic alternatives, and evolving treatment paradigms. The company's beta of 1.21 suggests higher volatility compared to the market. Indivior's focus on a critical healthcare need, combined with its financial performance, supports a positive investment outlook, contingent on managing regulatory and competitive pressures.

Growth Catalysts

• Upcoming: Potential FDA approval of new formulations or indications for existing products.
• Ongoing: Expansion of geographic reach into new markets with high unmet needs for addiction treatment.
• Ongoing: Development and launch of digital health solutions to improve patient adherence and outcomes.
• Ongoing: Strategic partnerships with healthcare providers and advocacy groups to increase awareness and access to treatment.

Risk Factors

• Potential: Increasing competition from generic alternatives to Suboxone Film.
• Potential: Changes in regulatory policies and treatment guidelines that could impact market access.
• Potential: Product liability claims related to the use of buprenorphine-based medications.
• Ongoing: Dependence on the opioid dependence treatment market, which is subject to evolving treatment paradigms.

Questions & Answers

Is INDV a good stock to buy?

Whether INDV is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Indivior Pharmaceuticals Inc's revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice—consult a qualified advisor before investing.

What is the INDV MoonshotScore?

The MoonshotScore rates INDV from 0 to 100 across growth potential, financial health, market momentum, and risk factors. It is updated as market data refreshes. This score is informational only—not a buy or sell recommendation.

How often is INDV data updated?

INDV's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update as market data refreshes.

What are the risks of investing in INDV?

Risk categories for INDV include market risk, company-specific risk, financial risk (debt, cash burn), and macroeconomic risk. Review the Risk Factors section for details specific to this stock. All investments carry risk of loss.